RATIONALE: To evaluate the safety of sublingual immunotherapy (SLIT) for peanut allergy using commercially prepared peanut cream. METHODS: We enrolled children aged <15 years who were diagnosed with peanut allergy by an open oral food challenge (OFC) and who agreed to undergo peanut SLIT. Doses of peanut protein from commercially prepared peanut cream were gradually increased from 13.8 mg/day to 4600 mg/day over the study period. We evaluated adverse events during SLIT and changes in maximum tolerated OFC doses from initiation to 12 months. RESULTS: Ten patients with a median age of 5.6 years (range: 5-13 years) were included in our study. One patient withdrew from the study; however, this was not due to an adverse event. Regarding adverse events, symptoms involving the oral cavity occurred in 7/10 cases (156/2045 dose times, 7.6%), and mild systemic symptoms occurred on an average at 0.1 times/case/year. The median maximum tolerated OFC dose increased significantly from 0.3 g (range: 0.1-0.5 g) to 0.4 g (range: 0.1-3.0) over 12 months (p50.034). In addition, the skin prick test wheal size decreased significantly from 1062.4 to 7.361.7 mm over 12 months (p50.006). Conversely, median peanut-specific IgE levels were not significantly different at 12 months (13.6 UA/ml) compared to baseline (13.5 UA/mL) (p50.43). CONCLUSIONS: SLIT using commercially prepared peanut cream resulted in only a few, mild adverse reactions and may increase tolerance to peanuts. Further studies are needed to evaluate the effectiveness of peanut SLIT.
Spectrum Health, Grand Rapids, MI. RATIONALE: The National Institute of Allergy and Infectious Disease (NIAID) published international consensus addendum guidelines on the early introduction of peanuts. One criticism of these guidelines is the shortage of allergists in the USA may prevent the practical institution of these guidelines. We designed a scheduling protocol to prioritize infants at high risk for peanut allergy. METHODS: We flagged every referral for patients <12 months old as urgent, regardless of reason. Four new patient appointments and two challenge slots were reserved weekly for these patients. If appointment was not available within two weeks a physician would review case to assess urgency. Evaluation and treatment was at the discretion of treating physician. We took a retrospective review July 2016-September 2018. RESULTS: 69 patients met criteria as ''high risk'' per NIAID guidelines and were evaluated in clinic on average 18.9 days (range 2-62 days) post referral. 31 patients were determined to need an in office peanut challenge for peanut introduction, with challenges happening on average 31.7 days (range 7-56 days) post referral. During this time period the 3rd next new patient slot for non-urgent appointments was on average 94.3 days. CONCLUSIONS: By automatically flagging new referrals in all children <12 months old and reserving clinic and challenge appointments for these children, we were able to systematically evaluate these children 75.4 days sooner than general referrals. Our unique scheduling method allowed us to prioritize patients at high risk for peanut allergy and helped decrease the risk of developing a peanut allergy while on the appointment wait list.
Implementation of Early Peanut Introduction Guidelines Among Pediatricians
David E. Tapke, MD, MPH, David R. Stukus, MD, FAAAAI, Benjamin T. Prince, MD, MSCI, Rebecca Scherzer, MD, FAAAAI, and Irene Mikhail, MD; Nationwide Children's Hospital, Columbus, OH. RATIONALE: Expert guidelines recommending early introduction of peanut before 12 months of age to infants at high risk for developing peanut allergy were published in January 2017. Guideline implementation in the primary care setting is unknown. METHODS: We conducted a retrospective chart review of infants with a suspected diagnosis of eczema or egg allergy that were seen for at least one well child visit between November 2017 and May 2018 within a large tertiary care medical center's primary care network. Infants with noneczematous dermatitis or mild eczema treated without prescription topical steroids were excluded. Records were reviewed for demographic information and details from each visit, including discussion of eczema and/or early peanut introduction. Allergy and dermatology visits were also reviewed, when applicable. RESULTS: Among 577 initial infants, 167 were excluded due to mild eczema and 138 were excluded for non-eczematous dermatitis. Of the 272 patients included in the final analysis, 174 were male, 249 had eczema, 11 had egg allergy and 12 had both. Eczema skin care was discussed in 148/ 240 (61.7%) of 4-month, 154/238 (64.7%) of 6-month and 89/172 (51.7%) of 9-month visits. Discussion of early peanut introduction occurred in 3.3% of 4-month, 3.3% of 6-month and 3.0% of 9-month visits. Early peanut introduction was discussed at well child visits only 21 times in 17 (6.3%) unique patients and always involved a referral to allergy. CONCLUSIONS: We identified very few instances of discussions about early peanut introduction in an at-risk population of infants seen in a large primary care network.
